1389P Two-year follow-up of KEYNOTE-365 cohort D: Pembrolizumab (pembro) plus abiraterone acetate (abi) and prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC)

Authors :: M. Linch
C. Ferrario
M. Stoeckle
B. Laguerre
J.A. Arranz Arija
T. Todenhöfer
P.C. Fong
J.M. Piulats Rodriguez
W. Berry
U. Emmenegger
L. Mourey
N. Mar
L.J. Appleman
A. Joshua
H.J. Conter
X.T. Li
C. Schloss
C.H. Poehlein
J.S. de Bono
E.Y. Yu
Source :: Annals of Oncology. 33:S1178
Publication Year :: 2022
Publisher :: Elsevier BV, 2022.

Full Text Access

Tools